BRCA2 gene mutations and coagulation-associated biomarkers

• DOI: 10.1160/th15-06-0520
• Publication Date: 2015-10-08T08:38:53Z
• Authors: Daniel Acosta; Juana María Santo...; Javier Modrego; Trinidad Caldés; Miguel de la Hoya; Eduardo Díaz-Rubio; Isabel Díaz-Millán; Natalia de las Heras; Luis Alfonso Rico...; Vicente Lahera; Olle Melander; Pedro Perez-Segura; José J Zamorano-León; Antonio López Farré
• Keywords: Adult; BRCA2 Protein; 0301 basic medicine; Heterozygote; Binding Sites; Haptoglobins; DNA Mutational Analysis; Transferrin; Fibrinogen; Breast Neoplasms; Middle Aged; Platelet Factor 4; 3. Good health; P-Selectin; 03 medical and health sciences; Case-Control Studies; Mutation; Humans; Female; Genetic Predisposition to Disease; Rad51 Recombinase; Blood Coagulation; Biomarkers

Thromboembolic events are the second cause of death in cancer patients, although mechanisms underlying this increased thromboembolic risk remain unclear. The aims study were to examine whether BRCA2 gene mutations may modify circulating levels thrombocoagulation biomarkers and breast development influence changes such biomarkers. was performed 25 women with (n=12 cancer, n=13 cancer-free) 13 non-mutant controls. Results revealed that plasma fibrinogen gamma chain isotypes 2 3, haptoglobin 4 5, serotransferrin 3 convertase C3/C5 5 significantly higher mutation carriers compared However, vitamin D binding protein isotype 1 alpha1-antitrypsin 2, decreased Plasma expression PF4 P-selectin than truncated conserving a region for RAD51 associated respect showing loss RD51 BRCA2. Only reduced alpha 1-antitrypsin cancer-free cancer. presence is thrombo-coagulating-related proteins, which independent development.